文献速递其他结缔组织病

系统性硬化症相关间质性肺病临床结局与生物学特征的性别差异:两项随机对照试验的事后分析

Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials.
PubMed 文献 · Lancet Rheumatol · 2022-09-21

对硬皮病肺研究SLS I和SLS II两项随机对照试验的事后分析显示,男性系统性硬化症相关间质性肺病患者在积极治疗和安慰剂治疗下,用力肺活量下降均较女性更差,长期生存更差,且支气管肺泡灌洗液中促纤维化介质浓度更高。

要点

  • SLS II中男性接受环磷酰胺或霉酚酸酯治疗时,3至12个月预测FVC下降速率均显著劣于女性。
  • SLS II中男性2年影像学纤维化结局更差,且男性性别与死亡率增加独立相关(HR 2.42)。
  • 男性支气管肺泡灌洗液中促纤维化介质升高,女性促炎介质升高。

核心结论

  • 在两项随机对照试验中,男性系统性硬化症相关间质性肺病患者无论是否接受积极治疗,间质性肺病病程均较女性更不利,长期生存也更差。
  • 促纤维化或炎症介质的性别差异可能解释这些差异,作者认为值得未来研究。

研究设计与样本

  • 对SLS I和SLS II两项随机对照试验所有参与者数据的事后分析。
  • SLS I中158名参与者(111名女性、47名男性)随机接受口服环磷酰胺(≤2 mg/kg每日)或安慰剂。
  • SLS II中142名参与者(105名女性、37名男性)随机接受口服霉酚酸酯(1500 mg每日两次)或口服环磷酰胺(≤2 mg/kg每日)。
  • 性别由参与者自我报告,主要目标为探索性别对24个月研究期间积极治疗中及治疗后预测FVC百分比变化的影响。

主要发现

  • SLS I安慰剂组中,男性3至12个月预测FVC下降速率大于女性,但差异未达统计学显著(估计效应-0.29,95%CI -0.67至0.10;p=0.14)。
  • SLS II中,男性接受环磷酰胺治疗者3至12个月预测FVC下降速率显著劣于女性(估计效应-0.72,95%CI -1.14至-0.31;p=0.00060)。
  • SLS II中,男性接受霉酚酸酯治疗者3至12个月预测FVC下降速率显著劣于女性(估计效应-0.34,95%CI -0.58至-0.10;p=0.0051)。
  • SLS I和SLS II合并积极治疗组及SLS I安慰剂组中,男性预测FVC下降≥10%的比例高于女性。
  • SLS II中男性2年影像学结局较女性更差,即使调整基线疾病严重程度和治疗分组后仍如此;SLS I长期生存男性更差(log-rank检验p=0.080),SLS II男性更差(log-rank检验p=0.030)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Observational studies have shown that men with systemic sclerosis have an increased risk of interstitial lung disease (ILD) and mortality compared with women. However, previous studies have not controlled for treatment effect or evaluated the biological mechanism or mechanisms underlying this sex difference. We aimed to compare ILD progression and long-term morbidity and mortality outcomes in male and female participants of two randomised controlled trials for systemic sclerosis-associated ILD. METHODS: For this post-hoc analysis, data from all participants in the Scleroderma Lung Study (SLS) I and SLS II were analysed. The primary objective was to explore the effect of sex on the course of the percentage predicted forced vital capacity (FVC) during and after active treatment over the 24-month study periods. In SLS I, 158 participants (111 women, 47 men) were randomly assigned to receive oral cyclophosphamide (cyclophosphamide; ≤2 mg/kg daily) or placebo; in SLS II, 142 participants (105 women, 37 men) were randomly assigned to receive oral mycophenolate mofetil (1500 mg twice daily) or oral cyclophosphamide (≤2 mg/kg daily). Sex (ie, male or female) was self-reported in both studies by the participants. Changes in radiographic fibrosis and time to death and respiratory failure were secondary outcomes of the present analysis. Baseline levels of biomarkers implicated in the pathobiology of systemic sclerosis-associated ILD were measured in bronchoalveolar lavage fluid in SLS I. FINDINGS: In the SLS I placebo group, the rate of decline in percentage predicted FVC from 3 months to 12 months was greater in men than in women, but the difference was not significant (estimated effect -0·29 [95% CI -0·67 to 0·10]; p=0·14). In SLS II, the rate of decline in percentage predicted FVC from 3 months to 12 months was significantly worse in men treated with either cyclophosphamide (estimated effect -0·72; [95% CI -1·14 to -0·31]; p=0·00060) or mycophenolate mofetil (estimated effect -0·34 [-0·58 to -0·10]; p=0·0051) than in women. A greater proportion of men had a decline in percentage predicted FVC of 10% or greater compared with women for the pooled active treatment groups from SLS I and SLS II and the placebo group of SLS I. Men had worse radiographic outcomes at 2 years than women in SLS II, even after adjusting for baseline disease severity and treatment arm assignment. Long-term survival was worse in men in SLS I (log-rank test p=0·080) and SLS II (log-rank test p=0·030). In SLS II, male sex was independently associated with increased mortality (hazard ratio 2·42 [95% CI 1·16 to 5·04]; p=0·018). In bronchoalveolar lavage fluid, men had increased concentrations of pro-fibrotic mediators (eg, matrix metalloproteinase-13 and tissue inhibitor of metallopeptidase 1), whereas women had increased pro-inflammatory mediators (eg, interleukin [IL]-12, IL-7, and granulocyte-colony stimulating factor). INTERPRETATION: In two randomised controlled trials, men with systemic sclerosis-associated ILD had a less favourable course of ILD both with and without active treatment, as well as worse long-term survival. Sex differences in pro-fibrotic or inflammatory mediators of disease might account for these differences and warrant future study. FUNDING: US National Institutes of Health; US National Heart, Lung, and Blood Institute; US National Institute of Arthritis and Musculoskeletal and Skin Diseases; Bristol Myers Squibb; and Hoffmann-LaRoche.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Volkmann ER, Tashkin DP, Silver R, et al. Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. Lancet Rheumatol. 2022. PMID: 37745675. doi:10.1016/s2665-9913(22)00193-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。